Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of pegylated interferon alfa-2a (R422) in chronic hepatitis B
jRCT2080220384Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2080220384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220384.